Polymorphism and overexpression of HER2/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India

[1]  J. Chang-Claude,et al.  Role of genetic polymorphisms and ovarian cancer susceptibility , 2009, Molecular oncology.

[2]  D. Pinto,et al.  The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. , 2005, Biochemical and biophysical research communications.

[3]  Gordon Mills,et al.  Integrative epidemiology: from risk assessment to outcome prediction. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Allen D. Roses,et al.  Pharmacogenetics and drug development: the path to safer and more effective drugs , 2004, Nature Reviews Genetics.

[5]  R. Roskoski.  The ErbB/HER receptor protein-tyrosine kinases and cancer. , 2004, Biochemical and biophysical research communications.

[6]  N. Dalay,et al.  Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. , 2004, Experimental and molecular pathology.

[7]  A. Gadducci,et al.  Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data , 2004, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[8]  R. Millikan,et al.  HER2 Codon 655 Polymorphism and Risk of Breast Cancer in African Americans and Whites , 2003, Breast Cancer Research and Treatment.

[9]  C. Lopes,et al.  Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome , 2003, International Journal of Clinical Oncology.

[10]  T. Halvorsen,et al.  Survival and Prognostic Factors in Patients With Ovarian Cancer , 2003, Obstetrics and gynecology.

[11]  Sarel J. Fleishman,et al.  A putative molecular-activation switch in the transmembrane domain of erbB2 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Matsuo,et al.  Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. , 2001, Journal of the National Cancer Institute.

[13]  A. Cheung,et al.  Comment on: Population-based case-control study of HER2 genetic polymorphism and breast cancer risk by Xie D. et al. , 2002 .

[14]  M. Wolff,et al.  Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. , 2001, Cancer letters.

[15]  H. McLeod,et al.  Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. , 2000, Journal of the National Cancer Institute.

[16]  X. Shu,et al.  Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. , 2000, Journal of the National Cancer Institute.

[17]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[18]  M. Sliwkowski,et al.  Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.

[19]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Rajewsky,et al.  G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. , 1991, Nucleic acids research.

[21]  C. la Vecchia,et al.  The epidemiology of ovarian cancer. , 1991, Gynecologic oncology.

[22]  R. Müllenbach,et al.  An efficient salt-chloroform extraction of DNA from blood and tissues. , 1989, Trends in genetics : TIG.

[23]  D. Stern,et al.  Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo , 1988, Molecular and cellular biology.

[24]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[25]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[26]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.